Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
 - EconoTimes)
PHOENIX, March 10, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute an inter partes review of U.S. Patent Nos. 8,486,972, 8,835,459 and 8,835,460, which cover the fentanyl formulation of SUBSYS® (fentanyl sublingual spray).
“SUBSYS is the first and only sublingual spray available for breakthrough cancer pain. This dismissal is indicative of the pioneering efforts by Insys to bring innovative therapies to patients to manage their underlying constant cancer pain,” said Dr. John N. Kapoor, Chairman, President and Chief Executive Officer of Insys. “As a Company, we remain committed to the defense and vigorous enforcement of our intellectual property estate with the goal of creating long-term shareholder value.”
In addition to the four U.S. patents granted by the United States Patent and Trademark Office, Insys was recently granted one additional U.S. Patent 9,241,935 covering the SUBSYS formulation, further strengthening the SUBSYS patent estate.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys seeks to address the clinical shortcomings of existing commercial products. Insys currently markets one product: SUBSYS® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
SUBSYS® and SYNDROS™ are trademarks of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: [email protected]
